

Soluble triggering receptor expressed on myeloid cell-1 (sTREM-1): a potential biomarker for the diagnosis of infectious diseases

Changlin Cao¹, Jingxian Gu², Jingyao Zhang (✉)^{2,3}

¹Department of Pulmonary Medicine, Chenzhou No.1 People's Hospital, Chenzhou 423000, China; ²Department of Hepatobiliary Surgery, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China; ³Department of SICU, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China

© Higher Education Press and Springer-Verlag Berlin Heidelberg 2017

Abstract Sensitive and useful biomarkers for the diagnosis and prognosis of infectious diseases have been widely developed. An example of these biomarkers is triggering receptor expressed on myeloid cell-1 (TREM-1), which is a cell surface receptor expressed on monocytes/macrophages and neutrophils. TREM-1 amplifies inflammation by activating the TREM-1/DAP12 pathway. This pathway is triggered by the interaction of TREM-1 with ligands or stimulation by bacterial lipopolysaccharide. Consequently, pro-inflammatory cytokines and chemokines are secreted. Soluble TREM-1 (sTREM-1) is a special form of TREM-1 that can be directly tested in human body fluids and well-known biomarker for infectious diseases. sTREM-1 level can be potentially used for the early diagnosis and prognosis prediction of some infectious diseases, including infectious pleural effusion, lung infections, sepsis, bacterial meningitis, viral infections (e.g., Crimean Congo hemorrhagic fever and dengue fever), fungal infections (e.g., *Aspergillus* infection), and burn-related infections. sTREM-1 is a more sensitive and specific biomarker than traditional indices, such as C-reactive protein and procalcitonin levels, for these infectious diseases. Therefore, sTREM-1 is a feasible biomarker for the targeted therapy and rapid and early diagnosis of infectious diseases.

Keywords soluble triggering receptor expressed on myeloid cells-1; infectious diseases; diagnosis and prognosis; biomarker

Introduction

Triggering receptor expressed on myeloid cell-1 (TREM-1), discovered by Bouchon *et al.* [1] in 2000, is a new immunoglobulin superfamily member that can be selectively expressed on the surface of a few subsets of myeloid lineage cells, including neutrophils and monocytes. TREM-1 is a transmembrane glycoprotein encoded by *TREM* genes located on human chromosome 6 and mouse chromosome 17 [2,3]. Five *TREM* genes have been discovered; *TREM-1–TREM-4* encode functional type I transmembrane globulin [4]. Unlike other members of the immunoglobulin superfamily, TREM-1 contains one extracellular Ig-like domain from residues Glu17 to Thr133; TREM-1 also contains a 70-amino-acid neck region linked to a 29-amino-acid transmembrane region and a 5-amino-acid intracellular region [2,3].

Soluble triggering receptor expressed on myeloid cell-1 (sTREM-1) is a soluble TREM-1 that can be directly measured and tested in human body fluids, including serum, pleural effusion, sputum, and urine, during infections [1,2,5]. sTREM-1 lacks the transmembrane region but possesses the same extracellular region as TREM-1; therefore, the former can combine with the same ligands as the latter [2,5]. The origin of sTREM-1 has been explained with two hypotheses. In one of these hypotheses, sTREM-1 is encoded by a splice variant of the mRNA of TREM-1 [6]. Gingras *et al.* [5] found that the third exon is deleted in this variant. In the other hypothesis, sTREM-1 is generated through the proteolytic cleavage of mature cell-surface-anchored TREM-1 [7]. Regardless of the sTREM-1 source, the function of sTREM-1 in various diseases is important.

TREM-1 expression is upregulated in bacterial and fungal infection cases but is poorly expressed in non-infectious inflammatory diseases [8,9]. TREM-1 expression can be stimulated by bacterial lipopolysaccharide in infections and innate immune responses [8]. TREM-1

modulates inflammatory responses primarily through the DNA-activating protein 12 (DAP12) signaling pathway [1,10]. TREM-1/DAP12 pathway can be activated by recognizing soluble cell lysates induced by exogenous pathogens [11]. In addition to invading pathogens, endogenous ligands on cellular surfaces can be recognized by TREM-1; however, this phenomenon remains unexplored [11]. Concurrently, sTREM-1 exhibits anti-inflammatory properties and exerts a decay activity to activate TREM-1 in binding ligands for TREM-1 receptors [6]. As an immunoreceptor tyrosine-based activation motif (ITAM)-bearing transmembrane adapter protein expressed on the surface of natural killer cells and myeloid cells, DAP12 contains a short extracellular domain of only 13–16 amino acids; by comparison, DAP12-associating receptors possess long extracellular domains [12,13]. These receptors, including myeloid DAP12-associating lectin-1 (MDL-1), TREM receptor family, and signal regulatory protein β 1 (SIRP β 1), consist of small cytoplasmic regions without signal transduction functions [12]. When DAP12 and its receptor form a complex, the cytoplasmic ITAM of DAP is phosphorylated, and the signaling pathway is consequently stimulated [5]. Receptor complexes then lead to the degranulation of neutrophils and release of interleukin (IL)-8, monocyte chemoattractant protein-1, and tumor necrosis factor (TNF)- α , which can initiate and amplify inflammatory responses [1] (Fig. 1). The activation of neutrophils and monocytes then causes a series of intracellular changes, including calcium mobilization and tyrosine phosphorylation, which help amplify inflammation [1]. sTREM-1 levels can be measured through ELISA, and TREM-1 receptor expression on the surface of myeloid cells in blood or other body fluids can be determined through flow cytometry [11]. sTREM-1 levels, which can precisely correspond to the changes in

TREM-1, can also be detected. TREM-1/sTREM-1 probably plays an important role in infectious diseases. Moreover, the single-nucleotide polymorphisms of TREM-1 are associated with the susceptibility and prognosis of different diseases, such as coronary artery disease (CAD), sepsis, septic shock, infective endocarditis, and intestinal Behcet's disease [14–19] (Table 1). However, sTREM-1 may participate in non-infectious diseases, which are discussed in a separate section. The underlying mechanism has yet to be fully clarified. Although the source of sTREM-1 remains elusive, the potential role of sTREM-1 in regulating infectious diseases has been extensively investigated. In this paper, different views on this component are summarized to discuss the close connection between sTREM-1 and infectious diseases.

sTREM-1 and infectious pleural effusion

Pleural effusion is a common complication of various diseases. The gold standard for diagnosing pleural effusions is Light's Criteria, which can differentiate a transudate from an exudate but is unable to identify fluid etiology [20]. Although numerous medical tests can help determine the pleural effusion etiology, it remains challenging. A new specific biomarker for diagnosing pleural effusion is urgently needed in clinical practice. Sim and Huang *et al.* [21,22] found that sTREM-1 levels in pleural fluid greatly exceed those in serum because they reflect the local inflammatory process, which is higher than the systemic one. Liu *et al.* [23] found that the sTREM-1 levels are significantly higher in para-pneumonic effusions than in tuberculous effusions. Similarly, Chan *et al.* [24] found that pleural sTREM-1 at a cut-off value of 374 pg/ml yields a sensitivity of 93.8% and a specificity of 90.9% in




Fig. 1 Schematic of the signaling transduction of the TREM-1/DAP12 pathway. Unknown ligands, such as LPS, link to the Ig-V domain of TREM-1 under stimuli. Next, two glutamic acid residues (D⁻) within the membrane of DAP12 interact with two lysine residues (K⁺) of the TREM-1 transmembrane domain, thereby causing immunoreceptor tyrosine-based activation motifs (ITAM) on DAP12 to bind to protein tyrosine kinases, such as Syk and ZAP70. These protein tyrosine kinases cause the phosphorylation of ITAM, which activates inflammatory reactions downstream. (Schematic was drawn based on references [9, 11–13].)

Table 1 Single-nucleotide polymorphisms (SNPs) of TREM-1 associated with different diseases

Disease	Nationality	SNP	Reference
TREM-1 and coronary artery disease	Russian	rs4711668	Kutikhin <i>et al.</i> [13]
	Russian	rs2234237, rs6910730, rs9471535, rs4711668, rs1817537, rs2234246, rs3804277	Golovkin <i>et al.</i> [14]
TREM-1 and susceptibility to septic shock	Chinese	rs2234246	Peng <i>et al.</i> [15]
	Chinese	rs7768162, rs9471535, rs2234237	Chen <i>et al.</i> [16]
TREM-1 and sepsis prognosis	Chinese	rs2234237	Su <i>et al.</i> [17]
TREM-1 and the development of intestinal Behcet's disease	Korean population	rs9471535, rs3789205, rs2234237	Jung <i>et al.</i> [18]
TREM-1 and skin involvement of intestinal Behcet's disease	Korean population	rs9471535, rs3789205, rs2234237	Jung <i>et al.</i> [18]
TREM-1 and the risk of azathioprine use of intestinal Behcet's disease	Korean population	rs9471535, rs3789205, rs2234237	Jung <i>et al.</i> [18]

differentiating bacterial pleural effusion from tuberculous pleurisy. Huang *et al.* [22] included 109 patients and demonstrated the similarity between sensitivity and specificity in distinguishing bacterial effusions from effusions with other etiologies when a cut-off value is settled at 768.1 pg/ml. In bacterial pleural effusion, sTREM-1 levels are higher in empyema than in parapneumonic effusions [24]. As a result, sTREM-1 has been proven a useful biomarker in the differential diagnosis of the etiology of pleural effusions. Moreover, Determann *et al.* [25] proved that sTREM-1 has advantages in detecting infections compared with C-reactive protein (CRP), a recognized indicator in the past. However, Porcel *et al.* [26] assert that sTREM-1 is not superior to CRP in separating infectious from non-infectious states. Notable differences in cut-off values can be attributed to the different specimen collection methods and the lack of standardization of the ELISA technique. However, most of these studies still supported the notion that pleural sTREM-1, at an appropriate cut-off value, can help differentiate between bacterial effusions and effusions from other etiologies. In conclusion, sTREM-1 may help clinicians to make an early diagnosis of empyema and guide the application of antibiotics.

sTREM-1 and lung infections

The early diagnosis of lung infections remains challenging, particularly in clearly identifying the cause of disease, because microbiological studies are often negative; this may delay the definitive diagnosis for 24–48 h. Novel methods are required to help clinicians make rapid and accurate diagnoses. Phua *et al.* [27] demonstrated that serum sTREM-1 levels are elevated in community-acquired pneumonia (CAP). Porfyridis *et al.* [28] found that early serum levels of sTREM-1 greater than 180 pg/ml in CAP are associated with unfavorable prognosis, supporting the results by Phua. Among CAP patients receiving treatment, Chao *et al.* [29] found that the level of

sTREM-1 remained elevated in the non-response group, but rapidly decreased in the response group. A recent study demonstrated that high levels of serum sTREM-1 indicated poor outcomes in TB patients [30]. sTREM-1 level is a good predictor of the prognosis of lung infection patients. Moreover, sTREM-1 has great value in diagnosing numerous lung infections, such as lower respiratory tract infections [31,32]. Additionally, sTREM-1 assay in alveolar and peritoneal fluids is useful for assessing pulmonary and peritoneal infections in critical-state patients and discriminating between pulmonary and extra-pulmonary infections during acute respiratory failure [33]. sTREM-1 can be detectable and exists at different levels in sera and other body fluids, as well as pathological fluid at local inflammatory sites; moreover, it is associated with numerous diseases at a staggering rate and could generate new clinical applications and provide more scientific ideas in studying this biomarker. sTREM-1 might be a potent biomarker closely related to the entire lung infection process.

Studies have been conducted of sTREM-1 and ventilator-associated pneumonia (VAP), a pneumonia that occurs more than 48 h after the initiation of endotracheal intubation and mechanical ventilation; moreover, it is the most common complication in intubated patients and substantially increases ICU patient mortality rate [34]. An overestimation of VAP occurs when the diagnosis is based on clinical suspicion and results in unnecessary antibiotic therapy [35]. Dupuy *et al.* [36] reported that sTREM-1 might be a potent biomarker in antibiotic therapy in the future. Tests using sTREM-1 may help in diagnosing and eliminating unnecessary antibiotic exposure in the patient. Gibot *et al.* [37,38] found that rapid detection of sTREM-1 in bronchial alveolar lavage (BAL) fluid is useful for differentiating patients receiving mechanical ventilation for bacterial or fungal pneumonia from those without pneumonia, particularly for patients with atypical manifestations. Furthermore, sTREM-1 levels in non-directed bronchial lavage fluid (NBLF) increased significantly during a 6-day period until the day of VAP diagnosis,

suggesting that a cut-off value of 200 pg/ml preceded by an increase of 100 pg/ml is diagnostic for pneumonia in ventilated patients [39]. Moreover, sTREM-1 can be detected in the exhaled ventilator condensate (EVC) collected from the expiratory line of patients receiving mechanical ventilation. The study demonstrated that sTREM-1 detection in EVC may improve the ability of clinicians to distinguish patients with VAP from those without pneumonia; however, further research is needed on account of the small study sample [40]. Similar results were proven in the diagnosis of VAP in patients after cardiac surgery [41]. These results showed the wide clinical prospect of sTREM-1 in VAP. Moreover, a prospective observational study by Grover *et al.* [42] demonstrated that a biomarker panel, including cellular and soluble TREM-1, could differentiate VAP from non-VAP more precisely than by detecting a single biomarker, although the level of sTREM-1 is significantly more elevated in VAP than in non-VAP. Similar to other diseases, sTREM-1 concentrations in BAL fluid can prompt prognosis in VAP patients. A study that included 35 VAP patients showed that dynamic sTREM-1 levels in BAL fluids during the first 7–9 days of VAP treatment had better prognostic ability than APACHE II scores in predicting outcomes, and this may help the physician in regulating antibiotic use [43].

However, not all studies support the use of detecting sTREM-1 in VAP patients. Two articles published in 2009 showed that the differences between the mean sTREM-1 concentrations in patients with definite VAP and those with definite absence of VAP or patients without confirmed VAP were not statistically significant, implying that measuring sTREM-1 in bronchial alveolar lavage fluid (BALF) samples as a diagnostic test for VAP may not be discriminative [44,45]. Several reasons may explain these inconsistent findings, including the different methods for sTREM-1 detection, different diagnostic criteria for VAP, and antibiotics use before sample collection. Therefore, studies with large populations using similar study designs, similar standardized study methods, sample collection, and analysis are necessary.

sTREM-1 and sepsis

Sepsis is a systemic response to infection. No gold standard exists for diagnosing sepsis because the traditional biological markers, like CRP and PCT, often overlap with other non-infectious causes of systemic inflammation, and no biological markers have been satisfactory [46–49]. The potential value of sTREM-1 in dealing with sepsis has attracted investigators' attention. Gibot *et al.* and other researchers [38,50,51] found that plasma sTREM-1 levels at a cut-off value of 60 ng/ml yield a positive success ratio of 8.6 and a negative likelihood ratio of 0.04 for

differentiating patients with sepsis from those with non-infectious cases with systemic inflammatory response syndrome. Moreover, sTREM-1 is of great value for early diagnosis and assessment of severity and prognosis of neonatal sepsis [52–54]. Furthermore, sTREM-1 level is a good predictor of septic patients [55,56]. Moreover, sTREM-1 might have value in exclusively diagnosing infections in postoperative patients with secondary peritonitis [57]. Giamarellos-Bourboulis *et al.* [58] argued that sTREM-1 kinetics are similar to IL-10, which play an anti-inflammatory role in the septic process. Thus, sTREM-1 protects the body during inflammation. They hypothesized that changes in sTREM-1/TNF- α ratios could determine the progression from sepsis, to severe sepsis, and to septic shock [58]. A prospective cohort study showed that sTREM-1 levels in survivors are lower than those in non-survivors and yielded a sensitivity of 85.7% and a specificity of 75.7% at a cut-off value of 252.05 pg/ml, demonstrating that sTREM-1 is a good prognostic indicator [59]. Zhang *et al.* [60] found that sTREM-1 levels are the more sensitive and specific index in the diagnoses and assessment of septic severity compared with CRP and PCT. Unfortunately, sTREM-1, along with PCT and CRP, could not determine whether new fevers are due to bacteria or not; however, the sTREM-1 level is able to assess the prognosis of bacteremia [61]. In contrast, sTREM-1 is a poor prognostic factor in patients with infection [62]. The ability of sTREM-1 in distinguishing sepsis from non-infectious SIRS was suspected in several studies [63–68]. However, when combined with other sepsis markers, the assay may significantly improve clinicians' ability to differentiate patients with sepsis from those with systemic inflammations of non-infectious origin [66,69]. In addition to serum sTREM-1, Su *et al.* [70] explored the diagnostic potential of urine sTREM-1 for early sepsis identification, severity prognosis assessment, and secondary acute kidney injury (AKI). TREM-1 testing is more sensitive than testing for WBC, serum CRP, and serum PCT during early sepsis diagnosis and is a good predictor for secondary AKI [70,71]. Moreover, Dai *et al.* [72,73] reported that sTREM-1 level is significantly increased in critically ill patients with sepsis-associated AKI compared with non-AKI septic patients whose predictive and diagnostic values were just as good as neutrophil gelatinase-associated lipocalin (NGAL) and cystatin-C (Cys-C), which are two traditional biomarkers. In addition to sepsis-related AKI, serum sTREM-1 is reported to be an independent risk factor for N-terminal pro-B-type natriuretic peptide (NT-proBNP) in sepsis-associated myocardial dysfunction [74,75]. sTREM-1 is closely related to the severity and prognosis of *Streptococcus pyogenes*-induced sepsis [76]. Therefore, sTREM-1 can be used in sepsis-associated organ dysfunction and other clinical conditions. In conclusion, sTREM-1 is a promising biomarker in clinical practice for sepsis.

sTREM-1 and bacterial meningitis

Bacterial meningitis has high morbidity and mortality [77]. Unfortunately, its diagnosis and treatment remain a conundrum for doctors because making a timely etiological diagnosis is difficult due to the cerebral spinal fluid cultures not being sensitive and, therefore, take long to process. The sTREM-1 level in cerebrospinal fluid (CSF) may be helpful as a biomarker for the presence of bacterial meningitis, leading to successful patient care. A retrospective cohort analysis showed that CSF sTREM-1 levels at a cut-off value of 20 pg/ml yield a sensitivity of 73%, a specificity of 77%, and an area under curve (AUC) of 0.82 when discriminating between patients with and without bacterial meningitis; moreover, CSF sTREM-1 levels are associated with prognosis [78]. sTREM-1 has been suggested to be upregulated in the CSF of patients with bacterial meningitis with high specificity [79]. The CSF sTREM-1 level may be helpful in diagnosing and prognosticating meningitis. Furthermore, Liu *et al.* [80] found sTREM-1 to be more rapid and accurate when they detected decoy receptor 3 (DcR3) and sTREM-1 in combination rather than sTREM-1 or DcR3 alone. However, current research on adults has small sample sizes, therefore, large-scale prospective studies are needed, particularly studies with children, to confirm the value of sTREM-1 measurement in diagnosing bacterial meningitis to assess its prognostic significance accurately.

Other infectious diseases

A recent study demonstrated that sTREM-1 level is significantly higher in patients with Crimean Congo hemorrhagic fever, a viral infection, than in the control group at a cut-off value of 405.9 pg/ml, with a sensitivity of 94.9% and a specificity of 87.5% [81]. Similarly, sTREM-1 level is significantly higher in dengue patients than healthy individuals [82]. sTREM-1 may be valuable in diagnosing viral infections apart from bacterial and fungal infections. Moreover, Cui *et al.* [83] demonstrated that plasma and BALF sTREM-1 are markedly elevated in immune-compromised *Aspergillus*-infected rat model. sTREM-1 might be a useful marker in infected burn wounds [84]. Therefore, sTREM-1 is associated with various infectious diseases, and is believed to be far more than discussed above. This inspires us to explore the pathogenesis of infection and sTREM-1.

Non-infectious diseases

sTREM-1 is an attractive molecule in infectious diseases and non-infectious inflammatory diseases. sTREM-1 is a crucial part of innate immune responses, which leads to the

release of pro-inflammatory cytokines and chemokines [85]. Essa *et al.* [86] found sTREM-1 levels, just like CRP and TNF- α , are significantly elevated in patients with chronic kidney disease on hemodialysis. sTREM-1 levels have been associated to bronchiectasis and disease-modifying anti-rheumatic drug (DMARD)-naive early rheumatoid arthritis (ERA), an autoimmune disease with chronic inflammation in the synovial joints [87–89]. In addition to pulmonary infection, sTREM-1 levels were reported to be increased significantly in patients with chronic obstructive pulmonary disease and differ in 3 clinical classifications [27]. Furthermore, TREM-1/sTREM-1 has a relationship with gout and febrile neutropenia [90,91]. Additionally, serum sTREM-1 is upregulated in inflammatory bowel disease patients, but its correlation to the disease activity remains uncertain [92,93]. In 2011, Hermus *et al.* [94] showed that sTREM-1 is increased in patients with CAD and peripheral artery disease (PAD). This study is the first to demonstrate the key role of sTREM-1 in atherosclerosis. Apart from benign diseases, TREM-1 expression is significantly high in several types of cancer. TREM-1 is expressed in hepatocellular carcinoma (HCC) cells and hepatic stellate cells, a type of tumor-associated cell; and TREM-1 is related to tumor progression and HCC prognosis [95,96]. Yuan *et al.* [97] found TREM-1 expression level is significantly high in patients with non-small cell lung cancer. TREM-1 is reported to be useful in differential diagnosis of craniopharyngioma [98]. In conclusion, sTREM-1 and TREM-1 are potential biomarkers for infectious and non-infectious diseases.

Conclusions

sTREM-1 is essential for myeloid cell-mediated inflammatory responses, as demonstrated by previous studies. Although the ability of sTREM-1 in diagnosing infectious diseases remains controversial, sTREM-1 detection is a promising technique for targeted therapy in sepsis diagnosis. The origin and release mechanisms of sTREM-1, particularly the molecular structure of its natural ligand and the accurate interaction between them, are unclear. However, we can predict these characteristics by using TREM-1, which is already known. TREM-1 forms a “head-to-tail” dimer with an extracellular V-type immunoglobulin-like domain (Ig-V) comprising approximately 120 amino acids [3,12]. The Ig-V, providing two possible binding sites for ligands, is followed by a region of approximately 70 amino acids that link to the transmembrane part of TREM-1 [99]. Additionally, TREM-1/DAP12 pathway affects both innate and adaptive immune responses, which provide insights into the clinical perspectives of sTREM-1 [12]. Further studies should focus on the molecular mechanisms of sTREM-1 and

infectious diseases to understand its interactions during redox reactions and with inflammatory factors. Additional evidence should also be obtained to support the predictive and prognostic role of sTREM-1 in infections from large-scale multi-center studies enrolling a substantial number of patients, particularly children and neonates. Fortunately, this molecule has been extensively investigated. These problems can be solved, and breakthroughs can be achieved in terms of the control and treatment of inflammatory diseases. sTREM-1 is a possible indispensable biomarker for clinical applications.

Acknowledgements

This study was supported by the National Natural Science Foundation of China (No. 81601672) and the Fundamental Research Funds for the Central Universities (No.1191320114). We are indebted to all individuals who participated in or helped with this research project.

Compliance with ethics guidelines

Changlin Cao, Jingxian Gu, and Jingyao Zhang declare that they have no competing interests. This manuscript is a review and does not involve a research protocol requiring approval from relevant institution review board or ethics committee.

References

1. Bouchon A, Dietrich J, Colonna M. Cutting edge: inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes. *J Immunol* 2000; 164(10): 4991–4995
2. Mahdy AM, Lowes DA, Galley HF, Bruce JE, Webster NR. Production of soluble triggering receptor expressed on myeloid cells by lipopolysaccharide-stimulated human neutrophils involves *de novo* protein synthesis. *Clin Vaccine Immunol* 2006; 13(4): 492–495
3. Radaev S, Kattah M, Rostro B, Colonna M, Sun PD. Crystal structure of the human myeloid cell activating receptor TREM-1. *Structure* 2003; 11(12): 1527–1535
4. Lemarié J, Barraud D, Gibot S. Host response biomarkers in sepsis: overview on sTREM-1 detection. *Methods Mol Biol* 2015; 1237: 225–239
5. Gingras MC, Lapillonne H, Margolin JF. TREM-1, MDL-1, and DAP12 expression is associated with a mature stage of myeloid development. *Mol Immunol* 2002; 38(11): 817–824
6. Palazzo SJ, Simpson T, Schnapp LM. Triggering receptor expressed on myeloid cells type 1 as a potential therapeutic target in sepsis. *Dimens Crit Care Nurs* 2012; 31(1): 1–6
7. Gómez-Piña V, Soares-Schanoski A, Rodríguez-Rojas A, Del Fresno C, García F, Vallejo-Cremades MT, Fernández-Ruiz I, Amalich F, Fuentes-Prior P, López-Collazo E. Metalloproteinases shed TREM-1 ectodomain from lipopolysaccharide-stimulated human monocytes. *J Immunol* 2007; 179(6): 4065–4073
8. Bouchon A, Facchetti F, Weigand MA, Colonna M. TREM-1 amplifies inflammation and is a crucial mediator of septic shock. *Nature* 2001; 410(6832): 1103–1107
9. Colonna M, Facchetti F. TREM-1 (triggering receptor expressed on myeloid cells): a new player in acute inflammatory responses. *J Infect Dis* 2003; 187(Suppl 2): S397–S401
10. Nochi H, Aoki N, Oikawa K, Yanai M, Takiyama Y, Atsuta Y, Kobayashi H, Sato K, Tateno M, Matsuno T, Katagiri M, Xing Z, Kimura S. Modulation of hepatic granulomatous responses by transgene expression of DAP12 or TREM-1-Ig molecules. *Am J Pathol* 2003; 162(4): 1191–1201
11. Tessarz AS, Cerwenka A. The TREM-1/DAP12 pathway. *Immunol Lett* 2008; 116(2): 111–116
12. Aoki N, Kimura S, Xing Z. Role of DAP12 in innate and adaptive immune responses. *Curr Pharm Des* 2003; 9(1): 7–10
13. Campbell KS, Colonna M. DAP12: a key accessory protein for relaying signals by natural killer cell receptors. *Int J Biochem Cell Biol* 1999; 31(6): 631–636
14. Kutikhin AG, Ponasenko AV, Khutornaya MV, Yuzhalin AE, Zhidkova II, Salakhov RR, Golovkin AS, Barbarash OL, Barbarash LS. Association of TLR and TREM-1 gene polymorphisms with atherosclerosis severity in a Russian population. *Meta Gene* 2016; 9: 76–89
15. Golovkin AS, Ponasenko AV, Khutornaya MV, Kutikhin AG, Salakhov RR, Yuzhalin AE, Zhidkova II, Barbarash OL, Barbarash LS. Association of TLR and TREM-1 gene polymorphisms with risk of coronary artery disease in a Russian population. *Gene* 2014; 550(1): 101–109
16. Peng LS, Li J, Zhou GS, Deng LH, Yao HG. Relationships between genetic polymorphisms of triggering receptor expressed on myeloid cells-1 and septic shock in a Chinese Han population. *World J Emerg Med* 2015; 6(2): 123–130
17. Chen Q, Zhou H, Wu S, Wang H, Lv C, Cheng B, Xie G, Fang X. Lack of association between TREM-1 gene polymorphisms and severe sepsis in a Chinese Han population. *Hum Immunol* 2008; 69(3): 220–226
18. Su L, Liu C, Li C, Jiang Z, Xiao K, Zhang X, Li M, Yan P, Feng D, Xie L. Dynamic changes in serum soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) and its gene polymorphisms are associated with sepsis prognosis. *Inflammation* 2012; 35(6): 1833–1843
19. Jung ES, Kim SW, Moon CM, Shin DJ, Son NH, Kim ES, Lee HJ, Hong SP, Kim TI, Kim WH, Cheon JH. Relationships between genetic polymorphisms of triggering receptor expressed on myeloid cells-1 and inflammatory bowel diseases in the Korean population. *Life Sci* 2011; 89(9-10): 289–294
20. Lam CW, Law CY. Pleural effusion lipoproteins measured by NMR spectroscopy for diagnosis of exudative pleural effusions: a novel tool for pore-size estimation. *J Proteome Res* 2014; 13(9): 4104–4112
21. Sim YS, Lee JH, Chun EM, Chang JH. Diagnostic utility of pleural fluid soluble triggering receptor expressed on myeloid cells 1 protein in patients with exudative pleural effusion. *Tuberc Respir Dis (Seoul)* 2007; 62(6): 499–505
22. Huang LY, Shi HZ, Liang QL, Wu YB, Qin XJ, Chen YQ. Expression of soluble triggering receptor expression on myeloid

- cells-1 in pleural effusion. *Chin Med J (Engl)* 2008; 121(17): 1656–1661
23. Liu CL, Hsieh WY, Wu CL, Kuo HT, Lu YT. Triggering receptor expressed on myeloid cells-1 in pleural effusions: a marker of inflammatory disease. *Respir Med* 2007; 101(5): 903–909
 24. Chan MC, Chang KM, Chao WC, Lin LY, Kuo BI, Hsu JY, Wu CL. Evaluation of a new inflammatory molecule (triggering receptor expressed on myeloid cells-1) in the diagnosis of pleural effusion. *Respirology* 2007; 12(3): 333–338
 25. Determann RM, Achouiti AA, El Solh AA, Bresser P, Vijfhuizen J, Spronk PE, Schultz MJ. Infectious pleural effusions can be identified by sTREM-1 levels. *Respir Med* 2010; 104(2): 310–315
 26. Porcel JM, Vives M, Cao G, Bielsa S, Ruiz-González A, Martínez-Iribarren A, Esquerda A. Biomarkers of infection for the differential diagnosis of pleural effusions. *Eur Respir J* 2009; 34(6): 1383–1389
 27. Phua J, Koay ES, Zhang D, Tai LK, Boo XL, Lim KC, Lim TK. Soluble triggering receptor expressed on myeloid cells-1 in acute respiratory infections. *Eur Respir J* 2006; 28(4): 695–702
 28. Porfyridis I, Plachouras D, Karagianni V, Kotanidou A, Papiris SA, Giamarellou H, Giamarellos-Bourboulis EJ. Diagnostic value of triggering receptor expressed on myeloid cells-1 and C-reactive protein for patients with lung infiltrates: an observational study. *BMC Infect Dis* 2010; 10(1): 286
 29. Chao WC, Wang CH, Chan MC, Chow KC, Hsu JY, Wu CL. Predictive value of serial measurements of sTREM-1 in the treatment response of patients with community-acquired pneumonia. *J Formos Med Assoc* 2007; 106(3): 187–195
 30. Huang CT, Lee LN, Ho CC, Shu CC, Ruan SY, Tsai YJ, Wang JY, Yu CJ. High serum levels of procalcitonin and soluble TREM-1 correlated with poor prognosis in pulmonary tuberculosis. *J Infect* 2014; 68(5): 440–447
 31. Shi JX, Li JS, Hu R, Li CH, Wen Y, Zheng H, Zhang F, Li Q. Diagnostic value of sTREM-1 in bronchoalveolar lavage fluid in ICU patients with bacterial lung infections: a bivariate meta-analysis. *PLoS One* 2013; 8(5): e65436
 32. Ye W, Hu Y, Zhang R, Ying K. Diagnostic value of the soluble triggering receptor expressed on myeloid cells-1 in lower respiratory tract infections: a meta-analysis. *Respirology* 2014; 19(4): 501–507
 33. Ramirez P, Kot P, Marti V, Gomez MD, Martinez R, Saiz V, Catala F, Bonastre J, Menendez R. Diagnostic implications of soluble triggering receptor expressed on myeloid cells-1 in patients with acute respiratory distress syndrome and abdominal diseases: a preliminary observational study. *Crit Care* 2011; 15(1): R50
 34. Davis KA. Ventilator-associated pneumonia: a review. *J Intensive Care Med* 2006; 21(4): 211–226
 35. Torres A, Ewig S. Diagnosing ventilator-associated pneumonia. *N Engl J Med* 2004; 350(5): 433–435
 36. Dupuy AM, Philippart F, Péan Y, Lasocki S, Charles PE, Chalumeau M, Claessens YE, Quenot JP, Guen CG, Ruiz S, Luyt CE, Roche N, Stahl JP, Bedos JP, Pugin J, Gauzit R, Misset B, Brun-Buisson C; Maurice Rapin Institute Biomarkers Group. Role of biomarkers in the management of antibiotic therapy: an expert panel review: I—currently available biomarkers for clinical use in acute infections. *Ann Intensive Care* 2013; 3(1): 22
 37. Gibot S, Cravoisy A, Levy B, Bene MC, Faure G, Bollaert PE. Soluble triggering receptor expressed on myeloid cells and the diagnosis of pneumonia. *N Engl J Med* 2004; 350(5): 451–458
 38. Siranović M, Kovac J, Gopcević S, Kelečić M, Kovac N, Rode B, Vucić M. Human soluble TREM-1: lung and serum levels in patients with bacterial ventilator associated pneumonia. *Acta Clin Croat* 2011; 50(3): 345–349
 39. Determann RM, Millo JL, Gibot S, Korevaar JC, Vroom MB, van der Poll T, Garrard CS, Schultz MJ. Serial changes in soluble triggering receptor expressed on myeloid cells in the lung during development of ventilator-associated pneumonia. *Intensive Care Med* 2005; 31(11): 1495–1500
 40. Horonenko G, Hoyt JC, Robbins RA, Singarajah CU, Umar A, Pattengill J, Hayden JM. Soluble triggering receptor expressed on myeloid cell-1 is increased in patients with ventilator-associated pneumonia: a preliminary report. *Chest* 2007; 132(1): 58–63
 41. Matsuno AK, Carlotti AP. Role of soluble triggering receptor expressed on myeloid cells-1 for diagnosing ventilator-associated pneumonia after cardiac surgery: an observational study. *BMC Cardiovasc Disord* 2013; 13(1): 107
 42. Grover V, Pantelidis P, Soni N, Takata M, Shah PL, Wells AU, Henderson DC, Kelleher P, Singh S. A biomarker panel (Bioscore) incorporating monocytic surface and soluble TREM-1 has high discriminative value for ventilator-associated pneumonia: a prospective observational study. *PLoS One* 2014; 9(10): e109686
 43. Wu CL, Lu YT, Kung YC, Lee CH, Peng MJ. Prognostic value of dynamic soluble triggering receptor expressed on myeloid cells in bronchoalveolar lavage fluid of patients with ventilator-associated pneumonia. *Respirology* 2011; 16(3): 487–494
 44. Anand NJ, Zuick S, Klesney-Tait J, Kollef MH. Diagnostic implications of soluble triggering receptor expressed on myeloid cells-1 in BAL fluid of patients with pulmonary infiltrates in the ICU. *Chest* 2009; 135(3): 641–647
 45. Oudhuis GJ, Beuving J, Bergmans D, Stobberingh EE, ten Velde G, Linssen CF, Verbon A. Soluble triggering receptor expressed on myeloid cells-1 in bronchoalveolar lavage fluid is not predictive for ventilator-associated pneumonia. *Intensive Care Med* 2009; 35(7): 1265–1270
 46. Balk RA, Bone RC. The septic syndrome. Definition and clinical implications. *Crit Care Clin* 1989; 5(1): 1–8
 47. Ayres SM. SCCM's new horizons conference on sepsis and septic shock. *Crit Care Med* 1985; 13(10): 864–866
 48. Brun-Buisson C. The epidemiology of the systemic inflammatory response. *Intensive Care Med* 2000; 26(0 Suppl 1): S64–S74
 49. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. *Chest* 1992; 101(6): 1644–1655
 50. Gibot S, Kolopp-Sarda MN, Béné MC, Cravoisy A, Levy B, Faure GC, Bollaert PE. Plasma level of a triggering receptor expressed on myeloid cells-1: its diagnostic accuracy in patients with suspected sepsis. *Ann Intern Med* 2004; 141(1): 9–15
 51. Richeldi L, Mariani M, Losi M, Maselli F, Corbetta L, Buonsanti C, Colonna M, Sinigaglia F, Panina-Bordignon P, Fabbri LM. Triggering receptor expressed on myeloid cells: role in the diagnosis of lung infections. *Eur Respir J* 2004; 24(2): 247–250
 52. Saldır M, Tunc T, Cekmez F, Cetinkaya M, Kalayci T, Fidancı K, Babacan O, Erdem G, Kocak N, Sari E, Akgül EO, Kul M. Endocan and soluble triggering receptor expressed on myeloid cells-1 as novel markers for neonatal sepsis. *Pediatr Neonatol* 2015; 56(6):

- 415–421
53. Arizaga-Ballesteros V, Alcorta-García MR, Lázaro-Martínez LC, Amézquita-Gómez JM, Alanís-Cajero JM, Villela L, Castorena-Torres F, Lara-Díaz VJ. Can sTREM-1 predict septic shock & death in late-onset neonatal sepsis? A pilot study. *Int J Infect Dis* 2015; 30: 27–32
 54. Adly AA, Ismail EA, Andrawes NG, El-Saadany MA. Circulating soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) as diagnostic and prognostic marker in neonatal sepsis. *Cytokine* 2014; 65(2): 184–191
 55. Ravetti CG, Moura AD, Vieira ÉL, Pedroso ÊR, Teixeira AL. sTREM-1 predicts intensive care unit and 28-day mortality in cancer patients with severe sepsis and septic shock. *J Crit Care* 2015; 30(2): 440.e7–440.e13
 56. Gibot S, Cravoisy A, Kolopp-Sarda MN, Béné MC, Faure G, Bollaert PE, Levy B. Time-course of sTREM (soluble triggering receptor expressed on myeloid cells)-1, procalcitonin, and C-reactive protein plasma concentrations during sepsis. *Crit Care Med* 2005; 33(4): 792–796
 57. Determann RM, van Till JW, van Ruler O, van Veen SQ, Schultz MJ, Boermeester MA. sTREM-1 is a potential useful biomarker for exclusion of ongoing infection in patients with secondary peritonitis. *Cytokine* 2009; 46(1): 36–42
 58. Giamarellos-Bourboulis EJ, Zakyntinos S, Baziaka F, Papadomichelakis E, Vrtzili S, Koutoukas P, Armaganidis A, Giamarellou H, Roussos C. Soluble triggering receptor expressed on myeloid cells 1 as an anti-inflammatory mediator in sepsis. *Intensive Care Med* 2006; 32(2): 237–243
 59. Li Z, Wang H, Liu J, Chen B, Li G. Serum soluble triggering receptor expressed on myeloid cells-1 and procalcitonin can reflect sepsis severity and predict prognosis: a prospective cohort study. *Mediators Inflamm* 2014; 2014: 641039
 60. Zhang J, She D, Feng D, Jia Y, Xie L. Dynamic changes of serum soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) reflect sepsis severity and can predict prognosis: a prospective study. *BMC Infect Dis* 2011; 11(1): 53
 61. Su L, Han B, Liu C, Liang L, Jiang Z, Deng J, Yan P, Jia Y, Feng D, Xie L. Value of soluble TREM-1, procalcitonin, and C-reactive protein serum levels as biomarkers for detecting bacteremia among sepsis patients with new fever in intensive care units: a prospective cohort study. *BMC Infect Dis* 2012; 12(1): 157
 62. Velásquez S, Matute JD, Gámez LY, Enríquez LE, Gómez ID, Toro F, Valencia ML, De La Rosa G, Patiño PJ, Jaimes FA. Characterization of nCD64 expression in neutrophils and levels of s-TREM-1 and HMGB-1 in patients with suspected infection admitted in an emergency department. *Biomedica* 2013; 33(4): 643–652
 63. Lin MT, Wei YF, Ku SC, Lin CA, Ho CC, Yu CJ. Serum soluble triggering receptor expressed on myeloid cells-1 in acute respiratory distress syndrome: a prospective observational cohort study. *J Formos Med Assoc* 2010; 109(11): 800–809
 64. Henriquez-Camacho C, Losa J. Biomarkers for sepsis. *BioMed Res Int* 2014; 2014: 547818
 65. Barati M, Bashar FR, Shahrami R, Zadeh MH, Taher MT, Nojomi M. Soluble triggering receptor expressed on myeloid cells 1 and the diagnosis of sepsis. *J Crit Care* 2010; 25(2): 362.e1–362.e6
 66. Kofoed K, Andersen O, Kronborg G, Tvede M, Petersen J, Eugen Olsen J, Larsen K. Use of plasma C-reactive protein, procalcitonin, neutrophils, macrophage migration inhibitory factor, soluble urokinase-type plasminogen activator receptor, and soluble triggering receptor expressed on myeloid cells-1 in combination to diagnose infections: a prospective study. *Crit Care* 2007; 11(2): R38
 67. Latour-Pérez J, Alcalá-López A, García-García MA, Sánchez-Hernández JF, Abad-Terrado C, Viedma-Contreras JA, Masiá M, González-Tejera M, Arizo-León D, Porcar MJ, Bonilla-Rovira F, Gutiérrez F. Diagnostic accuracy of sTREM-1 to identify infection in critically ill patients with systemic inflammatory response syndrome. *Clin Biochem* 2010; 43(9): 720–724
 68. Bopp C, Hofer S, Bouchon A, Zimmermann JB, Martin E, Weigand MA. Soluble TREM-1 is not suitable for distinguishing between systemic inflammatory response syndrome and sepsis survivors and nonsurvivors in the early stage of acute inflammation. *Eur J Anaesthesiol* 2009; 26(6): 504–507
 69. Gibot S, Cravoisy A, Dupays R, Barraud D, Nace L, Levy B, Bollaert PE. Combined measurement of procalcitonin and soluble TREM-1 in the diagnosis of nosocomial sepsis. *Scand J Infect Dis* 2007; 39(6-7): 604–608
 70. Su LX, Feng L, Zhang J, Xiao YJ, Jia YH, Yan P, Feng D, Xie LX. Diagnostic value of urine sTREM-1 for sepsis and relevant acute kidney injuries: a prospective study. *Crit Care* 2011; 15(5): R250
 71. Derive M, Gibot S. Urine sTREM-1 assessment in diagnosing sepsis and sepsis-related acute kidney injury. *Crit Care* 2011; 15(6): 1013
 72. Dai X, Zeng Z, Fu C, Zhang S, Cai Y, Chen Z. Diagnostic value of neutrophil gelatinase-associated lipocalin, cystatin C, and soluble triggering receptor expressed on myeloid cells-1 in critically ill patients with sepsis-associated acute kidney injury. *Crit Care* 2015; 19(1): 223
 73. Su L, Xie L, Liu D. Urine sTREM-1 may be a valuable biomarker in diagnosis and prognosis of sepsis-associated acute kidney injury. *Crit Care* 2015; 19(1): 281
 74. Tao F, Peng L, Li J, Shao Y, Deng L, Yao H. Association of serum myeloid cells of soluble triggering receptor-1 level with myocardial dysfunction in patients with severe sepsis. *Mediators Inflamm* 2013; 2013: 819246
 75. Zhou G, Ye L, Zhang L, Zhang L, Zhang Y, Deng L, Yao H. Association of myeloid cells of triggering receptor-1 with left ventricular systolic dysfunction in BALB/c mice with sepsis. *Mediators Inflamm* 2014; 2014: 391492
 76. Horst SA, Linnér A, Beineke A, Lehne S, Hóltje C, Hecht A, Norrby-Teglund A, Medina E, Goldmann O. Prognostic value and therapeutic potential of TREM-1 in *Streptococcus pyogenes*-induced sepsis. *J Innate Immun* 2013; 5(6): 581–590
 77. Nigrovic LE, Kuppermann N, Malley R. Development and validation of a multivariable predictive model to distinguish bacterial from aseptic meningitis in children in the post-*Haemophilus influenzae* era. *Pediatrics* 2002; 110(4): 712–719
 78. Determann RM, Weisfelt M, de Gans J, van der Ende A, Schultz MJ, van de Beek D. Soluble triggering receptor expressed on myeloid cells 1: a biomarker for bacterial meningitis. *Intensive Care Med* 2006; 32(8): 1243–1247
 79. Bishara J, Hadari N, Shalita-Chesner M, Samra Z, Ofir O, Paul M, Peled N, Pitlik S, Molad Y. Soluble triggering receptor expressed on myeloid cells-1 for distinguishing bacterial from aseptic meningitis in adults. *Eur J Clin Microbiol Infect Dis* 2007; 26(9): 647–650

80. Liu YJ, Shao LH, Zhang J, Fu SJ, Wang G, Chen FZ, Zheng F, Ma RP, Liu HH, Dong XM, Ma LX. The combination of decoy receptor 3 and soluble triggering receptor expressed on myeloid cells-1 for the diagnosis of nosocomial bacterial meningitis. *Ann Clin Microbiol Antimicrob* 2015; 14(1): 17
81. Altay FA, Elaldi N, Şentürk GÇ, Altın N, Gözel MG, Albayrak Y, Şencan İ. Serum sTREM-1 level is quite higher in Crimean Congo hemorrhagic fever, a viral infection. *J Med Virol* 2016; 88(9): 1473–1478
82. Ruiz-Pacheco JA, Vivanco-Cid H, Izaguirre-Hernández IY, Estrada-García I, Arriaga-Pizano L, Chacóin-Salinas R, Fonseca-Coronado S, Vaughan G, Ruiz Tovar K, Rivera-Osorio MP, Escobar-Gutiérrez A. TREM-1 modulation during early stages of dengue virus infection. *Immunol Lett* 2014; 158(1-2): 183–188
83. Wei M, Tu L, Liang Y, Liu J, Gong Y, Xiao D, Zhang Y. The effect of signal transduction pathway of triggering receptor-1 expressed on myeloid cells in acute lung injury induced by paraquat in rats. *Chin J Ind Hyg Occup Dis (Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi)* 2015; 33(9): 646–651 (in Chinese)
84. Burmistrova AL, Filippova IuFu. Soluble form of trigger receptor expressed on myeloid cells-1 as a marker of burn wound mixed infection. *Zh Mikrobiol Epidemiol Immunobiol* 2013; (6): 63–68 (in Russian)
85. Hasibeder A, Stein P, Brandwijk R, Schild H, Radsak MP. Evaluation and validation of the detection of soluble triggering receptor expressed on myeloid cells 1 by enzyme-linked immunosorbent assay. *Sci Rep* 2015; 5: 15381
86. Essa ES, Elzorkany KM. sTREM-1 in patients with chronic kidney disease on hemodialysis. *APMIS* 2015; 123(11): 969–974
87. Masekela R, Anderson R, de Boeck K, Vreys M, Steel HC, Olurunju S, Green RJ. Expression of soluble triggering receptor expressed on myeloid cells-1 in childhood CF and non-CF bronchiectasis. *Pediatr Pulmonol* 2015; 50(4): 333–339
88. Molad Y, Ofer-Shiber S, Pokroy-Shapira E, Oren S, Shay-Aharoni H, Babai I. Soluble triggering receptor expressed on myeloid cells-1 is a biomarker of anti-CCP-positive, early rheumatoid arthritis. *Eur J Clin Invest* 2015; 45(6): 557–564
89. Choi ST, Kang EJ, Ha YJ, Song JS. Levels of plasma-soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) are correlated with disease activity in rheumatoid arthritis. *J Rheumatol* 2012; 39(5): 933–938
90. Lee J, Lee SY, Lee J, Lee J, Baek S, Lee DG, Kim EK, Lee SH, Cho ML, Kwok SK, Ju JH, Park SH. Monosodium urate crystal-induced triggering receptor expressed on myeloid cells 1 is associated with acute gouty inflammation. *Rheumatology (Oxford)* 2016; 55(1): 156–161
91. Kwofie L, Rapoport BL, Fickl H, Meyer PW, Rheeder P, Hlope H, Anderson R, Tintinger GR. Evaluation of circulating soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) to predict risk profile, response to antimicrobial therapy, and development of complications in patients with chemotherapy-associated febrile neutropenia: a pilot study. *Ann Hematol* 2012; 91(4): 605–611
92. Park JJ, Cheon JH, Kim BY, Kim DH, Kim ES, Kim TI, Lee KR, Kim WH. Correlation of serum-soluble triggering receptor expressed on myeloid cells-1 with clinical disease activity in inflammatory bowel disease. *Dig Dis Sci* 2009; 54(7): 1525–1531
93. Saurer L, Rihs S, Birrer M, Saxer-Seculic N, Radsak M, Mueller C; Swiss IBD Cohort Study. Elevated levels of serum-soluble triggering receptor expressed on myeloid cells-1 in patients with IBD do not correlate with intestinal TREM-1 mRNA expression and endoscopic disease activity. *J Crohn's Colitis* 2012; 6(9): 913–923
94. Hermus L, Schuitemaker JH, Tio RA, Breek JC, Slart RH, de Boef E, Zeebregts CJ. Novel serum biomarkers in carotid artery stenosis: useful to identify the vulnerable plaque? *Clin Biochem* 2011; 44(16): 1292–1298
95. Liao R, Sun TW, Yi Y, Wu H, Li YW, Wang JX, Zhou J, Shi YH, Cheng YF, Qiu SJ, Fan J. Expression of TREM-1 in hepatic stellate cells and prognostic value in hepatitis B-related hepatocellular carcinoma. *Cancer Sci* 2012; 103(6): 984–992
96. Duan M, Wang ZC, Wang XY, Shi JY, Yang LX, Ding ZB, Gao Q, Zhou J, Fan J. TREM-1, an inflammatory modulator, is expressed in hepatocellular carcinoma cells and significantly promotes tumor progression. *Ann Surg Oncol* 2015; 22(9): 3121–3129
97. Yuan Z, Mehta HJ, Mohammed K, Nasreen N, Roman R, Brantly M, Sadikot RT. TREM-1 is induced in tumor associated macrophages by cyclo-oxygenase pathway in human non-small cell lung cancer. *PLoS One* 2014; 9(5): e94241
98. Liu Y, Wang CH, Li DL, Zhang SC, Peng YP, Peng JX, Song Y, Qi ST, Pan J. TREM-1 expression in craniopharyngioma and Rathke's cleft cyst: its possible implication for controversial pathology. *Oncotarget* 2016; 7(31): 50564–50574
99. Kelker MS, Foss TR, Peti W, Teyton L, Kelly JW, Wüthrich K, Wilson IA. Crystal structure of human triggering receptor expressed on myeloid cells 1 (TREM-1) at 1.47 Å. *J Mol Biol* 2004; 342(4): 1237–1248